摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(甲硫基)-2(1H)-嘧啶酮 | 129618-62-8

中文名称
4-(甲硫基)-2(1H)-嘧啶酮
中文别名
——
英文名称
4-(Methylthio)-2,3-dihydropyrimidin-2-one
英文别名
4-methylthiouracil;6-(Methylsulfanyl)pyrimidin-2(1h)-one;6-methylsulfanyl-1H-pyrimidin-2-one
4-(甲硫基)-2(1H)-嘧啶酮化学式
CAS
129618-62-8
化学式
C5H6N2OS
mdl
MFCD07732327
分子量
142.181
InChiKey
NALHPVUWRWEAQR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    66.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    4-(甲硫基)-2(1H)-嘧啶酮ferrous(II) sulfate heptahydrateammonium hydroxide 作用下, 反应 72.0h, 以77%的产率得到胞嘧啶
    参考文献:
    名称:
    A one-pot, water compatible synthesis of pyrimidine nucleobases under plausible prebiotic conditions
    摘要:
    以氰基乙炔为起点,在水中一锅形成 4-取代嘧啶核碱基的前生物合理途径。
    DOI:
    10.1039/c8cc09435g
  • 作为产物:
    描述:
    甲基亚硝基脲3-(dimethylamino)prop-2-enethioamide碳酸氢钠 作用下, 以 为溶剂, 反应 24.0h, 以22%的产率得到4-(甲硫基)-2(1H)-嘧啶酮
    参考文献:
    名称:
    A one-pot, water compatible synthesis of pyrimidine nucleobases under plausible prebiotic conditions
    摘要:
    以氰基乙炔为起点,在水中一锅形成 4-取代嘧啶核碱基的前生物合理途径。
    DOI:
    10.1039/c8cc09435g
点击查看最新优质反应信息

文献信息

  • [EN] AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANALOGUES D'AZAPYRIDONE UTILES COMME ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE CONCENTRANT LA MÉLANINE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2010104818A1
    公开(公告)日:2010-09-16
    MCHR1 antagonists are provided having the following Formula (I): A1 and A2 are independently C or N; E is C or N; Q1, Q2, and Q3 are independently C or N provided that at least one of Q1, Q2, and Q3 is N but not more than one of Q1, Q2, and Q3 is N; D1 is a bond, -CR8R9 X-, -XCR8R9-, -CHR8CHR9-, -CR10=CR10'-, -C≡C-, or 1,2-cyclopropyl; X is O, S or NR11; R1, R2, and R3 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF3, -OCF3, -OR12 and -SR12; G is O, S or -NR15; D2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkylcycloalkoxy or when G is NR15, G and D2 together may optionally form an azetidine, pyrrolidine or piperidine ring; Z1 and Z2 are independently hydrogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF3, -OCONR14R14', -CN, -CONR14R14', -SOR12, -SO2R12, -NR14COR14', -NR14CO2R14', -CO2R12, NR14SO2R12 or COR12; R5, R6, and R7 are independently selected from the group consisting of hydrogen lower alkyl, lower cycloalkyl, -CF3, -SR12, lower alkoxy, lower cycloalkoxy, -CN, -CONR14R14', SOR12, SO2R12, NR14COR14', NR14CO2R12, CO2R12, NR14SO2R12 and -COR12; R8, R9, R10, R10', R11 are independently hydrogen or lower alkyl; R12 is lower alkyl or lower cycloalkyl; R14 and R14' are independently H, lower alkyl, lower cycloalkyl or R14 and R14' together with the N to which they are attached form a ring having 4 to 7 atoms; and R15 is independently selected from the group consisting of hydrogen and lower alkyl. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.
    MCHR1拮抗剂具有以下化学式(I):A1和A2独立地为C或N;E为C或N;Q1、Q2和Q3独立地为C或N,但至少其中一个为N,但不超过一个为N;D1为键,-CR8R9 X-,-XCR8R9-,-CHR8CHR9-,-CR10=CR10'-,-C≡C-,或1,2-环丙基;X为O、S或NR11;R1、R2和R3独立地从氢、卤素、低烷基、低环烷基、-CF3、-OCF3、-OR12和-SR12组成的群体中选择;G为O、S或-NR15;D2为低烷基、低环烷基、低烷基环烷基、低环烷基烷基、低环烷氧基烷基或低烷基环烷氧基,或当G为NR15时,G和D2一起可以选择形成氮杂环丙烷、吡咯烷或哌啶环;Z1和Z2独立地为氢、低烷基、低环烷基、低烷氧基、低环烷氧基、卤素、-CF3、-OCONR14R14'、-CN、-CONR14R14'、-SOR12、-SO2R12、-NR14COR14'、-NR14CO2R14'、-CO2R12、NR14SO2R12或COR12;R5、R6和R7独立地从氢、低烷基、低环烷基、-CF3、-SR12、低烷氧基、低环烷氧基、-CN、-CONR14R14'、SOR12、SO2R12、NR14COR14'、NR14CO2R12、CO2R12、NR14SO2R12和-COR12组成的群体中选择;R8、R9、R10、R10'、R11独立地为氢或低烷基;R12为低烷基或低环烷基;R14和R14'独立地为H、低烷基、低环烷基或R14和R14'与其连接的N一起形成具有4至7个原子的环;R15独立地从氢和低烷基组成的群体中选择。这些化合物对于治疗MCHR1介导的疾病,如肥胖症、糖尿病、炎症性肠病、抑郁症和焦虑症非常有用。
  • Inhibitors of DNA Methyltransferase
    申请人:Wahhab Amal
    公开号:US20080132525A1
    公开(公告)日:2008-06-05
    The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.
    这项发明涉及抑制DNA甲基转移酶亚型DNMT1和DNMT3b2。该发明提供了用于抑制DNMT1和DNMT3b2的化合物和方法。
  • Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity
    作者:Steffi Noll、Marijeta Kralj、Lidija Šuman、Holger Stephan、Ivo Piantanida
    DOI:10.1016/j.ejmech.2008.06.002
    日期:2009.3
    The antiproliferative activity screening on human tumor cell lines of a series of modified uracil and cytosine bases as well as some corresponding acyclonucleosides, and comparison of structure–activity relationship revealed the importance of chemical reactivity of the substituent attached to the C5-position of uracil for the activity of studied compounds. Namely, the results obtained for the most
    一系列修饰的尿嘧啶和胞嘧啶碱基以及一些相应的无环核苷在人肿瘤细胞系中的抗增殖活性筛选,以及结构-活性关系的比较表明,尿嘧啶C5位上取代基的化学反应活性对于研究化合物的活性。即,对于活性最高的化合物5-(氯乙酰氨基)尿嘧啶(2)及其无环糖类似物18所获得的结果表明,反应性取代基与胸苷酸合酶机制内若干可能的靶标之间形成了共价键(半胱氨酸残基,酶的基本部分,N,N-亚甲基四氢叶酸或其反应性亚胺形式)是最可能的作用方式。另外,新型的C 5-取代的尿嘧啶衍生物6(5- [双-(2-对-甲氧基苄基硫乙基)胺]乙酰氨基尿嘧啶)通过未知的机制对HeLa和MiaPaCa-2细胞系表现出高的抗增殖活性。
  • Synthesis and Antiviral Evaluation of Novel 2,3-Dihydroxypropyl Nucleosides from 2- and 4-Thiouracils
    作者:Adel A.-H. Abdel-Rahman、Abd-Allah SH. El-Etrawy、Ahmed E.-S. Abdel-Megied、Ibrahim F. Zeid、El Sayed H. El Ashry
    DOI:10.1080/15257770802086898
    日期:2008.11.13
    chloride (2) afforded 2-[[(2,2-Dimethyl-1,3-dioxolan-4-yl) methyl]thio]pyrimidin-4(1H)-ones 3a-c and 4-[[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]thio] pyrimidin-2(1H)-ones 8a,b, respectively. Further alkylation with 2 and/or 2,3-O-isopropylidine-1-O-(4-toluenesulfonyl)-glycerol (4) gave the acyclo N-nucleosides 5a-c and 9a,b whose deprotection afforded 6a-c and 10a,b. 2-(Methylthio)pyrimidin-4(1H)-ones 11a-c
    用2,3-O-异亚丙基-2,3-二羟丙基氯(2)对2-硫尿嘧啶1a-c和4-硫尿嘧啶7a,b进行区域选择性烷基化,得到2-[[((2,2-二甲基-1,3-)二氧戊环-4-基)甲基]硫基]嘧啶-4(1H)-基3a-c和4-[[((2,2-二甲基-1,3-二氧戊环-4-基)甲基]硫基]嘧啶-2 (1H)-分别为8a,b。用2和/或2,3-O-异丙基-1--1-O-(4-甲苯磺酰基)-甘油(4)进一步烷基化得到无环N-核苷5a-c和9a,b,它们的脱保护得到6a-c和10a ,b。将2-(甲硫基)嘧啶-4(1H)-酮11a-c和4-(甲硫基)嘧啶-2(1H)-酮14a,b用2和/或4处理得到12a-c和15a,b将它们去保护得到13a-c和16a,b。用两个当量的2处理嘧啶-2,4(1H,3H)-二硫酮17a-c,得到2,4-双[[((2,2-二甲基-1,3-二氧杂戊-4-基)甲基]] [硫代]
  • A direct method for the preparation of 2-hydroxyethoxymethyl derivatives of guanine, adenine, and cytosine
    作者:Jorge R. Barrio、Jerry D. Bryant、Gene E. Keyser
    DOI:10.1021/jm00179a020
    日期:1980.5
    and 4-(methylthio)pyrimidin-2-one anions were similarly alkylated with iodomethyl [(trimethylsilyl)oxy]ethyl ether, and the products (1f and 2b) were transformed by treatment with methanolic NH3 at 110 degrees C into 9-[(2-hydroxyethoxy)methyl]adenine (1b) and 1-[(2-hydroxyethoxy)methyl]cytosine (2a), respectively. The syntheses of these analogues, heretofore difficult to prepare by a simple procedure
    在-63℃下用碘甲基[(三甲基甲硅烷基)氧基]乙醚将2-氯-6-碘嘌呤烷基化,然后在25℃下在二恶烷水溶液中用K2CO3处理9-取代的氯碘嘌呤,然后在150℃下用NH3进行处理。 ℃提供了9-[(2-羟基乙氧基)甲基]鸟嘌呤(1a),一种有效的抗1型单纯疱疹病毒的抗病毒剂,收率很高。还合成了其单磷酸酯(1g),它是在病毒感染的细胞中从1a酶促产生的。用碘甲基[(三甲基甲硅烷基)氧基]乙醚将6-氯嘌呤和4-(甲硫基)嘧啶-2-酮阴离子类似地烷基化,并通过在110℃下用甲醇NH3处理将产物(1f和2b)转化为9 -[[(2-羟基乙氧基)甲基]腺嘌呤(1b)和1-[((2-羟基乙氧基)甲基]胞嘧啶(2a)。
查看更多